HeimCRSP • NASDAQ
Crispr Therapeutics AG
41,72 $
30. jan., 12:37:20 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í BandaríkinHöfuðstöðvar: CH
Við síðustu lokun
41,21 $
Dagbil
41,28 $ - 42,58 $
Árabil
36,52 $ - 91,10 $
Markaðsvirði
3,56 ma. USD
Meðalmagn
1,97 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD)sep. 2024Breyting á/á
Tekjur
602,00 þ.
Rekstrarkostnaður
17,42 m.-4,77%
Nettótekjur
-85,94 m.23,37%
Hagnaðarhlutfall
-14,28 þ.
Hagnaður á hvern hlut
-1,0128,37%
EBITDA
-105,39 m.17,33%
Virkt skatthlutfall
-1,03%
Heildareignir
Heildarskuldir
(USD)sep. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
1,94 ma.11,26%
Heildareignir
2,26 ma.8,11%
Heildarskuldir
316,47 m.-11,86%
Eigið fé alls
1,94 ma.
Útistandandi hlutabréf
85,35 m.
Eiginfjárgengi
1,81
Arðsemi eigna
-11,98%
Ávöxtun eigin fjár
-12,57%
Breyting á handbæru fé
(USD)sep. 2024Breyting á/á
Nettótekjur
-85,94 m.23,37%
Handbært fé frá rekstri
-106,91 m.-168,25%
Reiðufé frá fjárfestingum
-161,60 m.-233,17%
Reiðufé frá fjármögnun
9,64 m.519,54%
Breyting á handbæru fé
-258,80 m.-411,81%
Frjálst peningaflæði
-80,67 m.-495,63%
Um
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Stofnsett
2013
Höfuðstöðvar
Vefsvæði
Starfsfólk
407
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd